Blueprint Medicines Corporation

NasdaqGS:BPMC Stock Report

Market Cap: US$5.8b

Blueprint Medicines Future Growth

Future criteria checks 5/6

Blueprint Medicines is forecast to grow earnings and revenue by 66.2% and 28% per annum respectively. EPS is expected to grow by 66.3% per annum. Return on equity is forecast to be 18.4% in 3 years.

Key information

66.2%

Earnings growth rate

66.3%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate28.0%
Future return on equity18.4%
Analyst coverage

Good

Last updated15 Mar 2024

Recent future growth updates

Recent updates

Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)

Feb 20

Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Jan 08
Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%

Dec 18
Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%

Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?

Nov 20
Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?

Jul 26
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?

Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Apr 16
Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 09
Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Dec 12
Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Nov 07
Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal

Sep 15

Blueprint to seek label expansion for systemic mastocytosis therapy after trial win

Aug 17

Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance

Aug 02

Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront

Jun 30

Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook

Feb 17
Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook

Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation

Nov 10
Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation

Calculating The Intrinsic Value Of Blueprint Medicines Corporation (NASDAQ:BPMC)

Oct 15
Calculating The Intrinsic Value Of Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines: What Now

Jun 21

Earnings and Revenue Growth Forecasts

NasdaqGS:BPMC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20268222311414215
12/31/2025599-161-88-2716
12/31/2024393-340-257-25616
12/31/2023249-507-453-437N/A
9/30/2023216-555-492-479N/A
6/30/2023226-554-515-505N/A
3/31/2023205-581-503-493N/A
12/31/2022204-558-511-502N/A
9/30/2022272-718-404-395N/A
6/30/2022230-702-367-361N/A
3/31/2022221-650-310-306N/A
12/31/2021180-644-302-299N/A
9/30/2021107-411-312-309N/A
6/30/2021828340407409N/A
3/31/2021809325369371N/A
12/31/2020794314384387N/A
9/30/2020811333361367N/A
6/30/202075-395-340-327N/A
3/31/202072-371-321-307N/A
12/31/201967-348-292-278N/A
9/30/201916-362-311-301N/A
6/30/20198-340-291-284N/A
3/31/201944-267-214-206N/A
12/31/201845-237-188-175N/A
9/30/201845-205-165-142N/A
6/30/201852-170-138-114N/A
3/31/201817-177-160-138N/A
12/31/201721-148-135-120N/A
9/30/201727-120N/A-104N/A
6/30/201726-99N/A-96N/A
3/31/201727-85N/A-86N/A
12/31/201628-72N/A-25N/A
9/30/201625-67N/A-19N/A
6/30/201622-63N/A-13N/A
3/31/201618-58N/A-6N/A
12/31/201511-56N/A-32N/A
9/30/20157-57N/A-30N/A
6/30/20153-56N/A-26N/A
3/31/20151-52N/A-24N/A
12/31/2014N/A-46N/A-35N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BPMC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: BPMC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BPMC is expected to become profitable in the next 3 years.

Revenue vs Market: BPMC's revenue (28% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: BPMC's revenue (28% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BPMC's Return on Equity is forecast to be low in 3 years time (18.4%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.